At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
LY3972406 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3972406 in Adults With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating LY3972406 and Placebo for Plaque Psoriasis. Completed, enrolled 33 participants across 12 sites.
Detailed Summary
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartDec 2023
First PostedDec 2023
Primary CompletionApr 2025
Study CompletionMay 2025
TodayJul 2026
First PostedDec 20, 2023
Enrollment StartDec 6, 2023
Primary CompletionApr 1, 2025
Study CompletionMay 6, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 2.5 years ago
Interventions
LY3972406drug
Administered orally
Placebodrug
Administered orally